P. Y. Dietrich
Articles
Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)
A. Conconi;Catherine Thieblemont, MD, PhD;G. Martinelli;A. J. M. Ferreri;L. Devizzi;F. Peccatori;M. Ponzoni;V. Filipazzi;P. Y. Dietrich;M. A. Gianni;Franco Cavalli, MD, FRCP;Emanuele Zucca, MD
March 1st 2002This phase II study aimed to evaluate the tolerability and activity of the monoclonal anti-CD20 antibody rituximab (Rituxan) in patients with either untreated or relapsed biopsy-proven extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, with measurable or evaluable disease.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 19th 2019 | Updated: November 22nd 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: July 29th 2015 | Updated: November 22nd 2024
Liver Abnormality in 28-Year-Old Patient
Published: November 8th 2024 | Updated: November 22nd 2024
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
